Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.

Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, Bille K, Bahadoran P, Giacchero D, Lacour JP, Boyle GM, Hayward NF, Bertolotto C, Ballotti R.

Oncotarget. 2013 Dec;4(12):2212-24.

2.
3.

Uniquely modified RNA oligonucleotides targeting STAT3 suppress melanoma growth both in vitro and in vivo.

Yang L, Ma X, Xiao L, Tang M, Weng X, Sun L, Cao Y.

Cancer Biol Ther. 2009 Nov;8(21):2065-72. Epub 2009 Nov 18.

PMID:
19823036
4.

STAT3 is necessary for proliferation and survival in colon cancer-initiating cells.

Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J.

Cancer Res. 2011 Dec 1;71(23):7226-37. doi: 10.1158/0008-5472.CAN-10-4660. Epub 2011 Sep 7.

5.

Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.

Han Z, Wang X, Ma L, Chen L, Xiao M, Huang L, Cao Y, Bai J, Ma D, Zhou J, Hong Z.

Oncotarget. 2014 Sep 30;5(18):8416-28.

6.

MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer.

Jiang J, Li Z, Yu C, Chen M, Tian S, Sun C.

Cancer Lett. 2015 Jan 28;356(2 Pt B):962-70. doi: 10.1016/j.canlet.2014.11.007. Epub 2014 Nov 10.

PMID:
25444909
7.

Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.

Bailet O, Fenouille N, Abbe P, Robert G, Rocchi S, Gonthier N, Denoyelle C, Ticchioni M, Ortonne JP, Ballotti R, Deckert M, Tartare-Deckert S.

Cancer Res. 2009 Apr 1;69(7):2748-56. doi: 10.1158/0008-5472.CAN-08-2690. Epub 2009 Mar 17.

8.

Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells.

Santini R, Vinci MC, Pandolfi S, Penachioni JY, Montagnani V, Olivito B, Gattai R, Pimpinelli N, Gerlini G, Borgognoni L, Stecca B.

Stem Cells. 2012 Sep;30(9):1808-18. doi: 10.1002/stem.1160.

9.

Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy.

Emeagi PU, Maenhout S, Dang N, Heirman C, Thielemans K, Breckpot K.

Gene Ther. 2013 Nov;20(11):1085-92. doi: 10.1038/gt.2013.35. Epub 2013 Jun 27.

PMID:
23804077
10.

6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells.

Liu L, Nam S, Tian Y, Yang F, Wu J, Wang Y, Scuto A, Polychronopoulos P, Magiatis P, Skaltsounis L, Jove R.

Cancer Res. 2011 Jun 1;71(11):3972-9. doi: 10.1158/0008-5472.CAN-10-3852. Epub 2011 May 24.

11.

Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS).

Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, Bille K, Robert C, Bressac-de Paillerets B, Hofman P, Rocchi S, Peyron JF, Lacour JP, Ballotti R, Bertolotto C.

Genes Dev. 2011 Jun 15;25(12):1245-61. doi: 10.1101/gad.625811. Epub 2011 Jun 6.

12.

Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling.

Cao HH, Tse AK, Kwan HY, Yu H, Cheng CY, Su T, Fong WF, Yu ZL.

Biochem Pharmacol. 2014 Feb 1;87(3):424-34. doi: 10.1016/j.bcp.2013.11.008. Epub 2013 Nov 23.

PMID:
24275163
13.

CD271 is an imperfect marker for melanoma initiating cells.

Cheli Y, Bonnazi VF, Jacquel A, Allegra M, De Donatis GM, Bahadoran P, Bertolotto C, Ballotti R.

Oncotarget. 2014 Jul 30;5(14):5272-83.

14.
15.

Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway.

Yang J, Liao D, Chen C, Liu Y, Chuang TH, Xiang R, Markowitz D, Reisfeld RA, Luo Y.

Stem Cells. 2013 Feb;31(2):248-58. doi: 10.1002/stem.1281.

16.

Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.

Mohan CD, Bharathkumar H, Bulusu KC, Pandey V, Rangappa S, Fuchs JE, Shanmugam MK, Dai X, Li F, Deivasigamani A, Hui KM, Kumar AP, Lobie PE, Bender A, Basappa, Sethi G, Rangappa KS.

J Biol Chem. 2014 Dec 5;289(49):34296-307. doi: 10.1074/jbc.M114.601104. Epub 2014 Oct 15.

17.

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.

Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N.

BMC Cancer. 2014 May 6;14:317. doi: 10.1186/1471-2407-14-317.

18.

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG, Weiss S.

Neuro Oncol. 2013 Feb;15(2):198-207. doi: 10.1093/neuonc/nos302. Epub 2012 Dec 21.

19.

Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma.

Cao HH, Chu JH, Kwan HY, Su T, Yu H, Cheng CY, Fu XQ, Guo H, Li T, Tse AK, Chou GX, Mo HB, Yu ZL.

Sci Rep. 2016 Feb 25;6:21731. doi: 10.1038/srep21731.

20.

SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.

Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, Facciolo F, Citro G, Strano S, Muti P, Blandino G, Cioce M.

Oncogene. 2012 Jun 28;31(26):3148-63. doi: 10.1038/onc.2011.485. Epub 2011 Oct 24.

PMID:
22020330

Supplemental Content

Support Center